Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application entities : Bristol-myers squibb company save search
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.27%
H: 3.89%
C: 2.55%
lung tumors cancer cell treatment application advanced
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.36%
H: 1.2%
C: 0.86%
drug opdivo review food application
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Published: 2023-05-30 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.71%
H: 1.14%
C: 0.54%
lung drug review food cancer cell treatment application
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Published: 2023-05-01 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.76%
H: 2.17%
C: 1.66%
reblozyl fda anemia license review treatment ema application
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Published: 2023-02-28 (Crawled : 16:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.27%
H: 0.2%
C: -1.2%
drug application opdivo license food nivolumab
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Published: 2022-10-21 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.0%
H: 3.08%
C: 2.64%
camzyos drug application food therapy
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Published: 2022-06-20 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
| Email alert
Add to watchlist
application therapy
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
treatment application opdivo cancer nivolumab
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
Published: 2022-03-25 (Crawled : 13:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
reblozyl application drug license
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi
Published: 2022-02-17 (Crawled : 13:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.15%
H: 0.41%
C: -0.16%
fda application drug license food fda acceptance
Global Cell & Gene Therapy Market Research Report 2022: Expanding Application for Cell & Gene Therapies & Growing Demand for CAR T- Cell Therapies
Published: 2022-02-01 (Crawled : 21:00) - prnewswire.com
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.53%
H: 0.21%
C: -0.07%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: 0.0%
ema application gene therapy research cel gene therapies report therapy growing t-cell
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Published: 2021-12-03 (Crawled : 12:30) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
transfusion application drug license food
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Published: 2021-10-01 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
treatment europe cardio mavacamten application
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.06%
H: 0.12%
C: -1.71%
phase 2 trial authorized application nivolumab
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Published: 2021-04-30 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -1.42%
H: 1.23%
C: 0.68%
food treatment drug application nivolumab urothelial carcinoma
U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Published: 2021-03-19 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.42%
H: 1.1%
C: 1.01%
food fda drug cardio fda acceptance mavacamten application
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
Published: 2021-01-20 (Crawled : 15:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.25%
H: 0.38%
C: -0.48%
therapy cancer food drug application nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.